Format

Send to

Choose Destination
J Endocrinol Invest. 2017 Jun;40(6):663-667. doi: 10.1007/s40618-017-0636-8. Epub 2017 Feb 25.

The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis.

Author information

1
Department of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. jessica.pepe@uniroma1.it.
2
Department of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
3
Rheumatology Unit, University of Foggia, Foggia, Italy.
4
CTO Andrea Alesini Hospital, ASL Roma 2, University of Rome 'Tor Vergata', Rome, Italy.
5
Policlinico Gemelli Hospital, Rome, Italy.
6
Rehabilitation Hospital, I.R.C.C.S Santa Lucia Foundation, Rome, Italy.
7
Department of Pediatrics, "Sapienza" University, Rome, Italy.
8
Department of Public Health and Infectious Diseases, Section Health Statistic, "Sapienza" University Rome, Rome, Italy.

Abstract

PURPOSE:

To investigate the effect of 18 months' parathyroid hormone 1-84 (PTH 1-84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis.

METHODS:

Thirty-seven postmenopausal women with osteoporosis (mean age 72.9 ± 8.1 years old) and 23 healthy controls (mean age 68.9 ± 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1-84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study.

RESULTS:

At baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 ± 259.7 vs. 260.3 ± 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 ± 1.7 vs. 5.7 ± 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1-84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1-84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 ± 1.6 vs. 6.0 ± 1.5 pg/ml, p = 0.53) and VEGF (260.3 ± 184.3 vs. 257.4 ± 107.1 pg/ml, p = 0.94).

CONCLUSIONS:

PTH (1-84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.

KEYWORDS:

Bone morphogenetic protein 4; Osteoporosis; Parathyroid hormone 1–84; Vessel endothelial growth factor

PMID:
28238166
DOI:
10.1007/s40618-017-0636-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center